Clinical Ink was founded in 2007 by the late Tommy Littlejohn, M.D., and Doug Pierce, who both passionately believed that Clinical Ink’s solutions would revolutionize clinical research by eliminating paper source documentation — the last hurdle to paperless clinical trials. Long before the iPad, Tommy and Doug envisioned an innovative tablet-based software application that would offer site users the familiar look and feel of the paper source while allowing electronic capture, validation, and sharing for cleaner, faster data.
Clinical Ink’s co-founders leveraged valuable perspectives and a unique mix of expertise to build an organization that could realize this vision. Tommy brought more than 20 years of experience as a clinical investigator, and Doug brought another 20 years of experience running a medical forms publishing business. From 2007 to 2010, Tommy’s experience as an active researcher for over 3,000 studies served as an anchor and filter through which all software decisions would pass, making the positive impact that Clinical Ink solutions have on sites a core aim. Doug’s experience with medical form design was equally important in developing an intuitive user experience through an application interface that was often tested with actual site users. If the tablet wasn’t at least as fast and easy to use as paper, the interface would be redesigned, always with the goal of reducing site workload. Today, Tommy and Doug’s vision has become a reality, as Clinical Ink continues to revolutionize clinical research with our innovative Lumenis™ platform. Clinical Ink remains committed to our founders’ goals of dramatically reducing the cost and complexity of clinical research for sites, sponsors, and patients.
Chief Executive Officer
As chief executive officer (CEO), Ed Seguine brings more than 20 years of experience as a clinical technology executive at big pharma and start-up organizations to the Clinical Ink team. Mr. Seguine joined Clinical Ink in late 2009 with the goal of creating a company that would eliminate problems caused by current paper-based processes and technologies.
Prior to joining Clinical Ink, he served as general manager, trial planning at Medidata Solutions, where he managed acquisition integration activities and product positioning prior to the company’s IPO. He also served as CEO of Fast Track Systems, where he oversaw the turnaround process and established early commercial successes for a novel product that became the rationale for acquisition by Medidata Solutions. Prior to Fast Track, Mr. Seguine was a founding manager of the Eli Lilly & Co. venture capital funds, e.Lilly and Lilly Bioventures, focusing on technology and biotech and device companies. Mr. Seguine has also been intimately involved with key industry initiatives, including CDISC and eClinical Forum. He is a frequent presenter at industry events and publishes regularly. Mr. Seguine earned a master of business administration from Indiana University-Bloomington and a bachelor’s degree in finance from Brigham Young University.
President & Co-Founder
Doug Pierce co-founded Clinical Ink in 2007 to revolutionize clinical trials by eliminating the complexities and costs associated with paper-based data capture processes. In his role as president and co-founder, Mr. Pierce brings more than 20 years of experience in digital forms technology and mobile data capture to lead the strategic direction, development, and evolution of Clinical Ink’s eSource suite.
Chief Commercial Officer
As chief commercial officer, Kirk McPoyle brings 25 years of experience in pharmaceutical and healthcare management to his role. Mr. McPoyle leads all Clinical Ink global sales activities to drive market adoption of the company’s industry-leading eSource and patient engagement products and solutions.
Mr. McPoyle joined Clinical Ink from Acurian, a patient recruitment organization where, as senior VP of business development, he was responsible for leading the commercial team to sales and implementation excellence. During his tenure, he created and implemented all commercial strategies, including those for customer approach, pricing, proposals and contracting. Prior to Acurian, Mr. McPoyle held several roles at IMS Health, a leading provider of business intelligence for the pharmaceutical and healthcare industry. As VP of commercial operations for the Americas, he was responsible for executing the commercial strategy across the Americas and overseeing the sales operations group and the development and orchestration of the organization’s customer loyalty program. Prior to IMS Health, Mr. McPoyle held roles of increasing responsibility in sales, national account management, and marketing, as well as senior management positions at TAP Pharmaceuticals.
Chief Business Officer
As chief business officer, Jonathan Andrus leads Clinical Ink’s solution management and compliance teams to help sponsors and CROs better leverage eSource, eCOA, and ePRO data. With more than 20 years of experience, Mr. Andrus brings extensive expertise developing eClinical services that integrate data and technology to help life science companies optimize study execution. At Clinical Ink, Mr. Andrus is responsible for P&L across Clinical Ink’s products and services, and he is also focused on building relationships and forging strategic partnerships with sponsors, CROs, regulatory bodies, and clinical research professionals.
Mr. Andrus joined Clinical Ink from Bioclinica where he led the eClinical Solutions Group to develop their current service offerings, including data management, quality management, implementation services, and IWRS. Prior to Bioclinica, Mr. Andrus worked in pharmaceutical consulting and with CROs focused on quality, data management, and validation. An active thought leader, blogger, and presenter, Jonathan served as chair of the Society for Clinical Data Management (SCDM) in 2008 and 2013 and currently serves as the society’s treasurer. He is also an active member of DIA (North American Advisory Council and Annual Conference Data/Data Standards Track Chair) and ASQ. He earned his bachelor’s and master’s degrees from Temple University’s College of Liberal Arts and Graduate School of Pharmacy and is a certified quality auditor (CQA) and certified clinical data manager (CCDM®).
Chief Financial Officer
As chief financial officer, Scott Miltenberger leads Clinical Ink’s accounting, business planning, and global financial operations. Mr. Miltenberger brings more than 20 years of financial management and technology industry experience, primarily in executive roles leading strategic global financial operations.
Prior to joining Clinical Ink, Mr. Miltenberger was chief financial officer for GPX Enterprises (GPX), a private equity firm focused on the sponsorship, development and management of selected investments, where he helped lead the company through a period of rapid growth. Prior to GPX, Mr. Miltenberger served as CFO for Elemica, a cloud-based software services company, where he led the company’s financial strategy and capital raising initiatives and was instrumental in the organization’s M&A activities. Prior to Elemica, he served as the founding CFO for a venture-backed healthcare services company and held a senior financial role at Novacare Employee Services, where he helped position the company for its IPO. Mr. Miltenberger began his career at Deloitte & Touche LLP. In addition to being a certified public accountant (CPA), Mr. Miltenberger holds a master of business administration in finance from Villanova University and a bachelor’s degree in economics and business from Lafayette College. He is active in many local business and youth sports organizations.
Partner, NovaQuest Capital Management
Partner, NovaQuest Capital Management
CEO, MindPath Care Centers
Managing Partner, FCA Venture Partners
CEO, Wolters Kluwer Health
Partner, Bingham Associates